ArticleBMC gastroenterology2026
The risk of digestive tract complications in patients with gastrointestinal lymphoma: a propensity score study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assessed the clinical characteristics of gastrointestinal bleeding (GIB), obstruction (GIO), and perforation (GIP) in patients with primary gastrointestinal lymphomas.
methodsA retrospective analysis was performed of 347 patients with primary gastrointestinal lymphomas admitted to the First Affiliated Hospital of Xi’an Jiaotong University Between January 2014 and January 2024. The clinical characteristics of GIB, GIO, and GIP were recorded. This study employed propensity score matching (PSM) to identify risk factors for gastrointestinal complications (GICs).
resultsIn our study of primary gastrointestinal lymphoma cohort, GICs occurred in 34.0% of patients. In our study, GIB occurred in 75 cases (21.6%), GIO occurred in 45 cases (12.9%) and GIP occurred in 28 cases (8.0%). PSM analysis indicated that decreased hemoglobin (112.57 ± 19.95 vs. 100.24 ± 23.20, P = 0.041) and LDH (272.00, 189.00-399.00 vs. 188.00, 166.00-230.90, P = 0.011) levels, as well as the presence of stomachache (P = 0.027) are high-risk factors for the development of GIB. Stomachache (28 [62.2%] vs. 37 [82.2%], P = 0.034), vomiting (12 [26.7%] vs. 21 [46.6%], P = 0.031), and endoscopic evidence of hyperplastic lesions (P = 0.022) are identified as high-risk factors for GIO. Moreover, patients with endoscopic findings of ulcerative lesions (4 [14.2%] vs. 12 [42.9%], p = 0.025), decreased hemoglobin levels (119.5 ± 22.32 vs. 102.79 ± 25.50, P = 0.012), stomachache (16 [57.1%] vs. 23 [82.1%], P = 0.048), and constipation (8 [28.6%] vs. 3 [10.7%], P = 0.043) are more likely to experience GIP.
conclusionThis study attempted to identify risk factors for GIB, GIO, and GIP in patients with primary gastrointestinal lymphoma through PSM analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.